KRAS and non-small cell lung carcinoma: Based on transcriptional, mutational, copy number, and proteomic data, KRAS mutated NSCLC patients are classified into three groups: one, including co-mutations in TP53 (KP); a second carrying inactivating mutations in the tumor suppressor liver kinase b1 (LKB1) (KL); and a third, with bi-allelic deletions of two tumor suppressor genes, CDKN2A and CDKN2B (KC) [24].